@article {10.3844/ojbsci.2024.330.335,
article_type = {journal},
title = {The Effect of Gliflozin Therapy on TNF-α Secretion by Cultured Monocytes in Patients with Diabetes},
author = {Kirichenko, Tatiana Vladimirovna and Bochkareva, Leyla Azimovna and Markina, Yuliya Vladimirovna and Tolstik, Taisiya Vladimirovna and Bogatyreva, Anastasia Ilyinichna and Markin, Alexander Mikhailovich and Tulskiy, Andrey Alexeyevich and Kuzina, Irina Alexandrovna and Nedosugova, Lyudmila Victorovna and Petunina, Nina Alexandrovna and Orekhov, Alexander Nikolaevich},
volume = {24},
number = {3},
year = {2024},
month = {Feb},
pages = {330-335},
doi = {10.3844/ojbsci.2024.330.335},
url = {https://thescipub.com/abstract/ojbsci.2024.330.335},
abstract = {Currently it’s well established that chronic inflammation is a key pathogenetic mechanism in the development of Type 2 diabetes. The study aims to explore the inflammatory response of monocytes in diabetic patients compared to healthy subjects, focusing on TNF-α and to investigate the impact of SGLT2 inhibitors on monocyte inflammation. The study included 20 patients with newly diagnosed type 2 diabetes and 20 control subjects aged 50-79 years old, all participants provided written informed consent upon the inclusion. The secretion of pro-inflammatory cytokine TNF-α in both non-stimulated and LPS-stimulated conditions by blood-derived monocytes at baseline and after 3 months of dapagliflozin therapy 10 mg daily was assessed. Monocytes were isolated using Ficoll gradient centrifugation and CD14+ cell magnetic separation. TNF-α concentration was measured using ELISA. Diabetic patients showed a significant increase in TNF-α secretion by cultured monocytes (both non-stimulated and LPS-stimulated) compared to control subjects. After a 3-month dapagliflozin therapy, there was a significant reduction in TNF-α secretion. The study concludes that monocytes in diabetic individuals exhibit pro-inflammatory activation. Additionally, the antidiabetic therapy using SGLT2 inhibitors showed efficacy in reducing the pro-inflammatory status of monocytes. This suggests that SGLT2 inhibitors could be beneficial not only for controlling glucose levels but also for preventing diabetes-associated diseases by addressing inflammation.},
journal = {OnLine Journal of Biological Sciences},
publisher = {Science Publications}
}